Targeted gene insertion for molecular medicine
- PMID: 18607557
- DOI: 10.1007/s00109-008-0381-8
Targeted gene insertion for molecular medicine
Abstract
Genomic insertion of a functional gene together with suitable transcriptional regulatory elements is often required for long-term therapeutical benefit in gene therapy for several genetic diseases. A variety of integrating vectors for gene delivery exist. Some of them exhibit random genomic integration, whereas others have integration preferences based on attributes of the targeted site, such as primary DNA sequence and physical structure of the DNA, or through tethering to certain DNA sequences by host-encoded cellular factors. Uncontrolled genomic insertion bears the risk of the transgene being silenced due to chromosomal position effects, and can lead to genotoxic effects due to mutagenesis of cellular genes. None of the vector systems currently used in either preclinical experiments or clinical trials displays sufficient preferences for target DNA sequences that would ensure appropriate and reliable expression of the transgene and simultaneously prevent hazardous side effects. We review in this paper the advantages and disadvantages of both viral and non-viral gene delivery technologies, discuss mechanisms of target site selection of integrating genetic elements (viruses and transposons), and suggest distinct molecular strategies for targeted gene delivery.
Similar articles
-
Adenovirus as an integrating vector.Curr Gene Ther. 2002 May;2(2):135-44. doi: 10.2174/1566523024605591. Curr Gene Ther. 2002. PMID: 12109211 Review.
-
Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives.J Transl Med. 2016 Oct 12;14(1):288. doi: 10.1186/s12967-016-1047-x. J Transl Med. 2016. PMID: 27729044 Free PMC article. Review.
-
Transposons for gene therapy!Curr Gene Ther. 2006 Oct;6(5):593-607. doi: 10.2174/156652306778520647. Curr Gene Ther. 2006. PMID: 17073604 Review.
-
The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors.Hum Gene Ther. 2011 Jun;22(6):761-74. doi: 10.1089/hum.2010.233. Epub 2011 Mar 25. Hum Gene Ther. 2011. PMID: 21247248 Free PMC article. Review.
-
Viral vectors for gene delivery and gene therapy within the endocrine system.J Endocrinol. 2000 Feb;164(2):103-18. doi: 10.1677/joe.0.1640103. J Endocrinol. 2000. PMID: 10657846 Review.
Cited by
-
Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors.Mol Ther. 2019 Dec 4;27(12):2195-2212. doi: 10.1016/j.ymthe.2019.08.006. Epub 2019 Aug 19. Mol Ther. 2019. PMID: 31494053 Free PMC article.
-
A transposon and transposase system for human application.Mol Ther. 2010 Apr;18(4):674-83. doi: 10.1038/mt.2010.2. Epub 2010 Jan 26. Mol Ther. 2010. PMID: 20104209 Free PMC article. Review.
-
Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.Hum Gene Ther. 2012 May;23(5):444-50. doi: 10.1089/hum.2011.167. Epub 2012 Jan 17. Hum Gene Ther. 2012. PMID: 22107246 Free PMC article. Clinical Trial.
-
Retargeting sleeping beauty transposon insertions by engineered zinc finger DNA-binding domains.Mol Ther. 2012 Oct;20(10):1852-62. doi: 10.1038/mt.2012.126. Epub 2012 Jul 10. Mol Ther. 2012. PMID: 22776959 Free PMC article.
-
Chromatin structure of two genomic sites for targeted transgene integration in induced pluripotent stem cells and hematopoietic stem cells.Gene Ther. 2013 Feb;20(2):201-14. doi: 10.1038/gt.2012.25. Epub 2012 Mar 22. Gene Ther. 2013. PMID: 22436965 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical